Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Chemotherapy-Induced Anemia Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
The global chemotherapy-induced anemia market is poised for growth, with expectations to increase from $2.21 billion in 2022 to $2.40 billion in 2023, reflecting a compound annual growth rate (CAGR) of 8.7%. The market is projected to reach $3.2 billion in 2027, with a CAGR of 7.6%.
In 2023, according to Cancer Research UK, the incidence of head and neck cancer in the UK is projected to increase by 3% between 2023 and 2025, with a 12% expected rise in deaths due to head and neck cancers during the same period. This underscores the importance of addressing chemotherapy-induced anemia as part of cancer treatment.
Innovation Takes Center Stage in the Chemotherapy-Induced Anemia Market
Product innovation is a notable trend in the chemotherapy-induced anemia market, with major companies striving to develop innovative products to bolster their market position. For instance, Astellas Pharma Inc., a Japan-based pharmaceutical company, and FibroGen, a US-based biotechnology company, received approval for EVRENZO (Roxadustat) in Japan to treat anemia of chronic kidney disease in adult patients not on dialysis. Furthermore, in May 2023, Roxadustat demonstrated promising topline results in a Phase III clinical trial in China for treating anemia in patients undergoing chemotherapy for non-myeloid cancers.
Regional Insights: North America Leads, Asia-Pacific Grows Fast
North America held the top position in the chemotherapy-induced anemia market in 2022. Nevertheless, Asia-Pacific is projected to be the fastest-growing region in the forecast period. The market report encompasses regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa. It includes countries like Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, the USA, Italy, Spain, and Canada.
Key Players in the Chemotherapy-Induced Anemia Market:
Several major players contribute to the chemotherapy-induced anemia market, including:
- Pfizer Inc.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Amgen Inc.
- Baxter International Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Astellas Pharma Inc.
- Fresenius Kabi AG
- Hospira Inc.
- Dr. Reddy's Laboratories Ltd.
- Biocon Ltd.
- 3SBio Group
- FibroGen Inc.
- Karger AG
- Avesthagen Ltd.
- Blausen Medical Communications Inc.
- Aileron Therapeutics Inc.
Rising R&D Expenditure Boosts the Market
Increasing research and development expenditure is expected to bolster the chemotherapy-induced anemia market. Such investments are essential for developing, designing, and enhancing treatments. In 2021, European health industries invested approximately 41.5 billion euros ($44.47 billion) in research and development, an increase from 2020. This investment drives innovation and the development of advanced drugs to address chemotherapy-induced anemia, supporting the market's growth.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 175 |
| Forecast Period | 2023-2027 |
| Estimated Market Value (USD) in 2023 | $2.4 Billion |
| Forecasted Market Value (USD) by 2027 | $3.2 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
Key Topics Covered
1. Executive Summary
2. Chemotherapy-Induced Anemia Market Characteristics
3. Chemotherapy-Induced Anemia Market Trends and Strategies
4. Chemotherapy-Induced Anemia Market - Macro Economic Scenario
4.1. Impact of High Inflation on Online Therapy Services Market
4.2. Ukraine-Russia War Impact on Online Therapy Services Market
4.3. COVID-19 Impact on Online Therapy Services Market
5.1. Global Chemotherapy-Induced Anemia Historic Market Size and Growth, 2017 - 2022, Value ($ Billion)
5.2. Global Chemotherapy-Induced Anemia Forecast Market Size and Growth, 2022 - 2027, 2032F, Value ($ Billion)
5.3. Global Chemotherapy-Induced Anemia Market Drivers and Restraints
5.3.1. Drivers of the Market
5.3.2. Restraints of the Market
6. Chemotherapy-Induced Anemia Market Segmentation
6.1. Global Chemotherapy-Induced Anemia Market, Segmentation by Anemia, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Mild Anemia
- Moderate Anemia
- Severe Anemia
- Life-Threatening Anemia
6.2. Global Chemotherapy-Induced Anemia Market, Segmentation by Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- RBC (Red Blood Cells) Transfusion
- Erythropoiesis-Stimulating Agents (ESAs)
- Iron Supplementation
6.3. Global Chemotherapy-Induced Anemia Market, Segmentation by End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Hospitals
- Ambulatory Surgical Centers
- Multispecialty Clinics
- Cancer Research Centers
- Cancer Rehabilitation Centers
7. Chemotherapy-Induced Anemia Market Regional and Country Analysis
7.1. Global Chemotherapy-Induced Anemia Market, Split by Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Chemotherapy-Induced Anemia Market, Split by Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/6js099
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
